22–23 Jul 2026
Heidelberg Congress Center
Europe/Berlin timezone

Compliance to a virtually supervised aerobic and resistance exercise program among Latina/Hispanic breast cancer survivors: The ROSA Trial

23 Jul 2026, 14:00
45m
Heidelberg Congress Center ( Heidelberg Congress Center )

Heidelberg Congress Center

Heidelberg Congress Center

Czernyring 20 69115 Heidelberg Germany
1 - Scientific Poster Poster Session

Speaker

Rebekah Wilson (Dana-Farber Cancer Institute, Division of Population Sciences, Department of Medical Oncology, Boston, MA, USA; Harvard Medical School, Boston, MA, USA)

Description

Introduction: Reporting exercise compliance within intervention trials is critical to establish realistic expectations and inform best practices for cancer survivors. This secondary analysis describes compliance to a virtually supervised, home-based 16-week aerobic and resistance exercise intervention among Latina/Hispanic breast cancer survivors (LHBCS).

Methods: This analysis includes 26 sedentary, overweight or obese LHBCS. The ROSA program was a thrice-weekly, 16-week intervention of virtually supervised, periodized aerobic (50-85% HRmax) and resistance (60-75% 1-RM) exercise. Exercise dosage was calculated as time×heart rate zone (aerobic) and sets×repetitions×load (resistance). Adherence was defined using relative dose intensity (RDI), a ratio of exercise dose completed to prescribed with an RDI ≥100% considered compliant. Apriori compliance cut points included attending ≥80% of sessions or completing ≥80% of sessions at planned dosage. Descriptive statistics are presented as mean±standard deviation, number (percentage), or median [interquartile range] as appropriate.

Results: Participants were 55.96±9.46 years old and overweight (27.85[10.40] kg/m2). Mean attendance was 92.71±10.58% where 23 (88.46%) participants attended ≥80% of sessions. The most common reason for non-attendance was illness (20.98%). Ten (38.46%) participants complied with the aerobic dose and four (15.38%) for resistance dose in ≥80% of sessions. Overall aerobic exercise RDI was 116.67[112.50]% with 29.51% of sessions requiring a dose reduction. Resistance exercise RDI was 89.88±13.77% and 55.03% of sessions required a dose reduction; additionally alternative resistance exercises were prescribed 14.74% of the time and not considered dose reductions. Planned aerobic dose was mostly not met due to low exercising heart rate (64.41%). For resistance exercise, load (41.60%) was commonly reduced due to general pain (34.38%).

Conclusion: Virtual supervised exercise is well attended and aerobic exercise over adhered to; however, resistance exercise often requires modification due to general pain among LHBCS. Exercise practitioners should adapt exercise on an as needed basis in a way that can be safely instructed remotely.

Keywords

Breast cancer, virtual exercise, survivorship, compliance.

Abstract submitters declaration yes
Conflict of Interest & Ethical Approval yes

Author

Rebekah Wilson (Dana-Farber Cancer Institute, Division of Population Sciences, Department of Medical Oncology, Boston, MA, USA; Harvard Medical School, Boston, MA, USA)

Co-authors

Brett Ranieri (Dana-Farber Cancer Institute, Division of Population Sciences, Department of Medical Oncology, Boston, MA, USA) Noah Chigier (Dana-Farber Cancer Institute, Division of Population Sciences, Department of Medical Oncology, Boston, MA, USA) Dr Paola Gonzalo-Encabo (Departamento de Ciencias Biomédicas, Área de Educación Física y Deportiva, Facultad de Medicina y Ciencias de la Salud, Universidad de Alcalá, Madrid, Spain.) Mary K. Norris (Dana-Farber Cancer Institute, Division of Population Sciences, Department of Medical Oncology, Boston, MA, USA) Jocelyn Greer (Dana-Farber Cancer Institute, Division of Population Sciences, Department of Medical Oncology, Boston, MA, USA) Christina M. Dieli-Conwright (Dana-Farber Cancer Institute, Division of Population Sciences, Department of Medical Oncology, Boston, MA, USA; Harvard Medical School, Boston, MA, USA)

Presentation materials

There are no materials yet.